M
Mablink Bioscience
Biotech & Life Sciences · Lyon, France · Founded 2018
Transforming cancer immunotherapy with next generation ADCs MoreLess
Mablink Bioscience S.A.S., founded in 2018 and based in France, specializes in the development of Antibody Drug Conjugates (ADCs), a new class of cancer drugs. The company leverages its patented PSARlink technology, which uses hydrophilic polysarcosine to overcome the hydrophobicity of cytotoxic payloads, thereby enhancing the overall hydrophilicity and stability of ADCs. This technology allows for a higher Drug-to-Antibody Ratio (DAR) of up to 16, optimizing the therapeutic index and efficacy against tumor cells. Mablink serves pharmaceutical companies and research institutions focused on oncology, offering a platform that can be easily integrated into various stages of ADC development. The company generates revenue through partnerships and licensing agreements, providing its proprietary technology and expertise to enhance the development of targeted cancer therapies.
Keywords: ADC, cancer treatment, PSARlink, hydrophilic polysarcosine, biotechnology, oncology, drug development, therapeutic index, DAR, pharmaceutical partnerships.
Company overview
Mablink Bioscience company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2018
- Headquarters
- Lyon, France
- Employees
- 35
- Open positions
- None listed
- Dealroom signal
- 58.8
Valuation & funding
Mablink Bioscience funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Oct 2023 | $0 | — | Eli Lilly | ↗ |
| SERIES A✓Equity / VC | Oct 2022 | $34M | $136M | Elaia · Fondation Fournier-Majoie · Crédit Agricole · Pertinence Invest | ↗ |
| SEED✓Equity / VC | Apr 2021 | $4.4M | $18M | Crédit Agricole · Turenne Capital · Pertinence Invest · Simba Sante 2 | — |
| SPINOUT✓Other financing | Jan 2018 | — | — | CNRS Innovation · PULSALYS · French National Centre for Scientific Research - CNRS · INSERM | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 35 |
Growth signals
Mablink Bioscience website traffic
Latest recorded traffic for Mablink Bioscience is 60 monthly website visits, down 88% over the last three months.
Comparisons
Mablink Bioscience compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Mablink Bioscience's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Mablink Bioscience has talent and traffic
In the news
Latest news about Mablink Bioscience
Recent press, funding announcements, and product moves mentioning Mablink Bioscience — open to read from the original sources.
Market sentiment
What the market is saying about Mablink Bioscience
An AI-synthesized read of the highest-engagement posts about Mablink Bioscience on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mablink Bioscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.